News | News By Subject | News by Disease News By Date | Search News
Get Our FREE
Industry eNewsletter
email:    
   

GlaxoSmithKline (GSK), Theravance, Inc. (THRX)'s Asthma Drug Improved Lung Function In Phase 3 Study



12/6/2013 7:19:40 AM

free biotech news Get the latest biotech news where you want it. Sign up for the free GenePool newsletter today!

GlaxoSmithKline Plc. (GSK: Quote,GSK.L) and Theravance Inc. (THRX: Quote) announced positive results from a phase III efficacy and safety study of fluticasone furoate "FF"/vilanterol "VI" designed to support a potential filing for an asthma indication for adults in the US. For the pre-specified primary endpoint of 0-24 hour weighted mean forced expiratory volume in one second (FEV1), FF/VI 100/25mcg demonstrated a statistically significant improvement in lung function compared with FF 100mcg (108ml, 95% CI 45, 171 p < 0.001) at the end of the 12 week treatment period.

Help employers find you! Check out all the jobs and post your resume.

Read at RTT News


comments powered by Disqus
RTT News
   
Asthma

ADD TO DEL.ICIO.US    ADD TO DIGG    ADD TO FURL    ADD TO STUMBLEUPON    ADD TO TECHNORATI FAVORITES